Cernostics Contracts with Geisinger Health Plan to Become an In-network Provider for TissueCypher® Barrett’s Esophagus Assay Pittsburgh, PA, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Cernostics, pioneer of the worlds’ first precision medicine test to predict future development risk of esophageal cancer from Barrett’s esophagus...

Cernostics Announces Formation of Distinguished Medical Advisory Board Including Top Specialists in All Facets of Esophageal Disease PITTSBURGH, PA, July 01, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Cernostics, developer of next-generation cancer diagnostics and prognostics, today announced the formation of a distinguished...

Blinded Independent Validation Study Highlights Effectiveness of Tissue Systems Pathology Test in Predicting Risk of Progression to Esophageal Cancer in Patients with Barrett's Esophagus Data Presented at DDW 2019 Demonstrate Test Potential to Identify Patients Who May Benefit from Increased Surveillance and Early Therapeutic Intervention  PITTSBURGH, PA, May 21, 2019 (GLOBE...